Brief: Hemostemix Says Kyle Makofka Has Resigned As CEO

Hemostemix

19/11/2019 13:55

Nov 19 (Reuters) - Hemostemix Inc  HEM.V :
    * HEMOSTEMIX PROVIDES CORPORATE UPDATE
    * HEMOSTEMIX INC - KYLE MAKOFKA HAS RESIGNED AS CO'S CEO
    * HEMOSTEMIX INC - COMMENCED SEARCH FOR A SUITABLE
REPLACEMENT AND
WILL ANNOUNCE ANY APPOINTMENT IN DUE COURSE
    * HEMOSTEMIX INC - ENTERED INTO AN AMENDED LICENSE AGREEMENT
DATED
SEPT 30, 2019 WITH ASPIRE HEALTH SCIENCE, LLC
    * HEMOSTEMIX - AMENDED LICENSE TO AMEND ORIGINAL LICENSE
GRANTING
ASPIRE EXCLUSIVE RIGHTS TO USE, SELL, IMPORT ACP-01 IN SOME
JURISDICTIONS
    * HEMOSTEMIX- UNDER TERMS, CO IS ENTITLED TO RECEIVE AN
UP-FRONT
PAYMENT OF $1 MILLION FROM ASPIRE WITHIN 30 DAYS OF DATE FIRST
WRITTEN IN AMENDED LICENSE
    * HEMOSTEMIX- CO,ASPIRE MAY TERMINATE AMENDED LICENSE IF
THERE IS
BREACH OF MATERIAL CONDITION/ BANKRUPTCY/INSOLVENCY OF CO,
ASPIRE TO AMENDED LICENSE
    * HEMOSTEMIX INC - WILL CONTINUE TO SEEK OTHER MEANS TO
REDUCE
COSTS AND WILL CONTINUE TO LOOK AT AVAILABLE FINANCING AND
RESTRUCTURING ALTERNATIVES

Source text for Eikon:  ID:nGNXb3Xs7z 
Further company coverage:  HEM.V 

 ((Reuters.Briefs@thomsonreuters.com;))